12,372 trials
Herpes Zoster
Primary: Anti-glycoprotein E (gE) Antibody Concentrations Expressed as Geometric Mean Concentrations (GMCs) in HZ/suSeq and HZ/suCoAd Groups, and Between-group Ratios — 47434.82…
Prostate Cancer · Prostate Adenocarcinoma
Primary: Number of Participants With Adverse Events — 0 Participants
Macular Degeneration
Primary: Change in Best Corrected Visual Acuity (BCVA) — 4.57; 6.37 Letters
Obesity, Overweight
Primary: Body Mass Index — 39.12; 40.48 kg/m2
Coronary Artery Bypass · Cardiopulmonary Bypass · Coronary Artery Disease
Primary: Plasma Troponin I at Baseline — 0.42; 0.17 ng/mL — p=0.993
Chronic Obstructive Pulmonary Disease
Primary: Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12 — 0.0611…
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Primary: Change in Pulmonary Vascular Resistance (PVR) Expressed as the Ratio of Geometric Means of End of Double-blind Treatment (EDBT) to Baseline — 0.77; 0.55; 0.78; 0.56…
Deep Partial-thickness Burn
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 46 Participants
Partial Seizures With or Without Secondary Generalization · Epilepsy
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 58.4; 57.0; 60.1; 26.6 percentage of participants
Tuberculosis, Pulmonary · Tuberculosis, Multidrug-Resistant · Tuberculosis, MDR
Primary: Number of Participants With Culture Negative Status by 8 Weeks — 70; 122 Participants — p=<0.001
Huntingtons Disease
Primary: Change From Baseline in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) Score-Z Score — 0.103; -0.367; -0.139; -1.173 Scores on a Scale
Healthy Volunteers (Meningococcal Infection)
Primary: Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination…
Esophageal Squamous Cell Carcinoma (ESCC)
Primary: Overall Survival (OS) — 17.2; 10.6 months — p=<0.0001
Type 2 Diabetic Patients
Primary: Change in Post-ischemic Forearm Blood Flow — 3.60; 1.00 ml/100ml — p=0.004
Platelet Dysfunction
Primary: Platelet Reactions Units Pre-DAPA Tx and Post-DAPA Tx — 160.93 PRU